Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…Abstract Number: 1135 • ACR Convergence 2024
Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…Abstract Number: 1137 • ACR Convergence 2024
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…Abstract Number: 1809 • ACR Convergence 2024
Melanocytes Are Driven Toward an Antigen Presentation Phenotype Through UV-Induced Keratinocyte Crosstalk and Exposure to Type I Interferons in Patients with Cutaneous Lupus Erythematosus
Background/Purpose: Cutaneous lupus erythematosus (CLE) encompasses various lesion morphologies, but photosensitivity and high type I interferon (IFN) responses are a unifying theme amongst all CLE…Abstract Number: 1977 • ACR Convergence 2024
Three-dimensional Stereophotogrammetry Has Utility in Tracking Upper Eyelid Involvement and Overall Disease Worsening in Patients with Craniofacial Localized Scleroderma
Background/Purpose: Craniofacial localized scleroderma’s (LoS) indolent and subtle course poses challenges in quantifying disease progression. Traditional serial photography and the Localized Scleroderma Cutaneous Assessment Tool…Abstract Number: 2197 • ACR Convergence 2024
Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare fibrosing autoimmune disease associated with significant morbidity and mortality. Data on treatment strategies is limited, primarily based…Abstract Number: L17 • ACR Convergence 2023
Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Over 50 years have passed since the last therapy was approved for cutaneous lupus erythematosus (CLE).1 Parenteral administration, off-label use, or toxicity with long-term…Abstract Number: 2448 • ACR Convergence 2023
UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes
Background/Purpose: Photosensitivity occurs in ~ 75% of lupus patients. Although ultraviolet (UV) light stimulates Type I interferon (IFN-I) in the skin, why lupus patients are…Abstract Number: 0307 • ACR Convergence 2023
Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is frequently complicated by rapidly progressive interstitial lung disease (ILD) and is life-threatening especially in the…Abstract Number: 0325 • ACR Convergence 2023
Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey
Background/Purpose: There is a paucity of data among a global population exploring the burden of CLE on patients, especially as compared to patients with SLE.…Abstract Number: 0894 • ACR Convergence 2023
The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light
Background/Purpose: SLE patients characteristically have a prominent type I interferon (IFN-I) signature in lesional and non-lesional skin. We recently demonstrated that, following a single exposure…Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
ACR Meeting Abstracts